Orexigen Sinks Despite Contrave Efficacy in Phase III Obesity Trial
Assistant Managing Editor
Orexigen Therapeutics Inc.'s Contrave hit its endpoints in the first of four Phase III studies, but concerns that the data missed the FDA's benchmark for efficacy in obesity sent shares of the San Diego-based company falling 15.7 percent.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST